Literature DB >> 21515744

Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone.

Jason S Troutt1, Robert W Siegel, Jinbiao Chen, John H Sloan, Mark A Deeg, Guoqing Cao, Robert J Konrad.   

Abstract

BACKGROUND: Glucose-dependent insulinotropic peptide (GIP) is an incretin peptide secreted by intestinal K cells that stimulates insulin secretion in a glucose-dependent manner. It is secreted as an active, intact 42-amino acid peptide GIP(1-42), which is rapidly degraded by dipeptidyl peptidase 4 to GIP(3-42), which is inactive. There is currently no described monoclonal antibody-based sandwich immunoassay to quantify concentrations of GIP(1-42), the active form of the peptide.
METHODS: To create a sandwich ELISA for GIP(1-42), we generated a monoclonal antibody specific for the intact N-terminus of the peptide, which was further optimized to increase its affinity. We used this antibody as a conjugate antibody in a sandwich ELISA and paired it with an anti-total GIP capture monoclonal antibody to create a dual monoclonal sandwich ELISA for GIP(1-42).
RESULTS: The sandwich ELISA was highly specific for GIP(1-42) and did not recognize GIP(3-42). The ELISA demonstrated a broad dynamic range and a lower limit of quantification of 5 ng/L. Using the ELISA, we were able to show that GIP(1-42) concentrations in healthy volunteers increased dramatically in the postprandial state compared to the fasting state. GIP(1-42) values were correlated with total GIP values overall; however, there was substantial interindividual variation.
CONCLUSIONS: The use of an N-terminal-specific monoclonal antibody in a sandwich ELISA format provides a robust and convenient method for measuring concentrations of GIP(1-42), the active form of the incretin hormone. This ELISA should help to improve our understanding of the role of GIP(1-42) in regulating glucose-dependent insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515744     DOI: 10.1373/clinchem.2010.159954

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Deriving functional human enteroendocrine cells from pluripotent stem cells.

Authors:  Katie L Sinagoga; Heather A McCauley; Jorge O Múnera; Nichole A Reynolds; Jacob R Enriquez; Carey Watson; Hsiu-Chiung Yang; Michael A Helmrath; James M Wells
Journal:  Development       Date:  2018-10-01       Impact factor: 6.868

Review 2.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

3.  Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.

Authors:  Jizu Yi; David Warunek; David Craft
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

4.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.

Authors:  Yan Q Chen; Thomas G Pottanat; Robert W Siegel; Mariam Ehsani; Yue-Wei Qian; Eugene Y Zhen; Ajit Regmi; William C Roell; Haihong Guo; M Jane Luo; Ruth E Gimeno; Ferdinand Van't Hooft; Robert J Konrad
Journal:  J Lipid Res       Date:  2020-06-02       Impact factor: 5.922

5.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Authors:  Francis S Willard; Jonathan D Douros; Maria Bn Gabe; Aaron D Showalter; David B Wainscott; Todd M Suter; Megan E Capozzi; Wijnand Jc van der Velden; Cynthia Stutsman; Guemalli R Cardona; Shweta Urva; Paul J Emmerson; Jens J Holst; David A D'Alessio; Matthew P Coghlan; Mette M Rosenkilde; Jonathan E Campbell; Kyle W Sloop
Journal:  JCI Insight       Date:  2020-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.